Cargando…

Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose

Although all current antipsychotics act by interfering with the action of dopamine at dopamine D2 receptors, two recent reports showed that 800 to 1000 mg of cannabidiol per day alleviated the signs and symptoms of schizophrenia, although cannabidiol is not known to act on dopamine receptors. Becaus...

Descripción completa

Detalles Bibliográficos
Autor principal:	Seeman, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315552/ https://www.ncbi.nlm.nih.gov/pubmed/27754480 http://dx.doi.org/10.1038/tp.2016.195

Ejemplares similares

High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?
por: Reynolds, Gavin P
Publicado: (2021)

Successful treatment of dopamine dysregulation syndrome with dopamine D(2) partial agonist antipsychotic drug
por: Mizushima, Jin, et al.
Publicado: (2012)

The novel atypical antipsychotic cariprazine demonstrates dopamine D(2) receptor‐dependent partial agonist actions on rat mesencephalic dopamine neuronal activity
por: Delcourte, Sarah, et al.
Publicado: (2018)

History of the dopamine hypothesis of antipsychotic action
por: Seeman, Mary V
Publicado: (2021)

Effects of Dopamine D(2) Receptor Partial Agonist Antipsychotic Aripiprazole on Dopamine Synthesis in Human Brain Measured by PET with L-[β-(11)C]DOPA
por: Ito, Hiroshi, et al.
Publicado: (2012)

Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?
por: Mohr, Pavel, et al.
Publicado: (2022)

Parkinson's Disease: Low-Dose Haloperidol Increases Dopamine Receptor Sensitivity and Clinical Response
por: Hudson, Craig J., et al.
Publicado: (2014)

Discovery research and development history of the dopamine D(2) receptor partial agonists, aripiprazole and brexpiprazole
por: Kikuchi, Tetsuro, et al.
Publicado: (2021)

13.2 CANNABIDIOL AS AN ANTIPSYCHOTIC DRUG
por: Guimaraes, Francisco, et al.
Publicado: (2018)

The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study
por: Hashimoto, Kojiro, et al.
Publicado: (2014)

Structure of the dopamine D(2) receptor in complex with the antipsychotic drug spiperone
por: Im, Dohyun, et al.
Publicado: (2020)

Molecular Imaging of Dopamine Partial Agonists in Humans: Implications for Clinical Practice
por: Hart, Xenia M., et al.
Publicado: (2022)

The Role of the Dopamine D2 Receptor in Form-Deprivation Myopia in Mice: Studies With Full and Partial D2 Receptor Agonists and Knockouts
por: Huang, Furong, et al.
Publicado: (2020)

S158. REWARD ALTERATIONS IN ANTIPSYCHOTIC NAïVE FIRST-EPISODE-PSYCHOSIS PATIENTS BEFORE AND AFTER TREATMENT WITH A PARTIAL DOPAMINE AGONIST
por: Tangmose, Karen, et al.
Publicado: (2018)

Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis
por: Siafis, Spyridon, et al.
Publicado: (2023)

STRUCTURE OF THE D(2) DOPAMINE RECEPTOR BOUND TO THE ATYPICAL ANTIPSYCHOTIC DRUG RISPERIDONE
por: Wang, Sheng, et al.
Publicado: (2018)

Effects of 2-bromoterguride, a dopamine D(2) receptor partial agonist, on cognitive dysfunction and social aversion in rats
por: Tarland, Emilia, et al.
Publicado: (2017)

Potent and Subtype-Selective Dopamine D(2) Receptor Biased Partial Agonists Discovered via an Ugi-Based Approach
por: Mallo-Abreu, Ana, et al.
Publicado: (2021)

Editorial: Novel antipsychotics within and beyond clinical trials: The treatment of overlapping psychiatric disorders with D3-D2 partial agonists
por: Németh, György, et al.
Publicado: (2022)

Cariprazine, A Dopamine D(2)/D(3) Receptor Partial Agonist, Modulates ABCG2-Mediated Multidrug Resistance in Cancer
por: Hussein, Noor, et al.
Publicado: (2018)

Affinity States of Striatal Dopamine D2 Receptors in Antipsychotic-Free Patients with Schizophrenia
por: Kubota, Manabu, et al.
Publicado: (2017)

Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D(2) receptors
por: Sykes, David A., et al.
Publicado: (2017)

Role of D3 dopamine receptors in modulating neuroanatomical changes in response to antipsychotic administration
por: Guma, Elisa, et al.
Publicado: (2019)

Dopamine in Autism Spectrum Disorders—Focus on D2/D3 Partial Agonists and Their Possible Use in Treatment
por: Mandic-Maravic, Vanja, et al.
Publicado: (2022)

𝒟-Amphetamine and Antipsychotic Drug Effects on Latent Inhibition in Mice Lacking Dopamine D(2) Receptors
por: Bay-Richter, C, et al.
Publicado: (2013)

Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study
por: Llorca, Pierre-Michel, et al.
Publicado: (2022)

The antipsychotic potential of cannabidiol: clinical implications for patients with psychosis and comorbid cannabis use disorder
por: Garel, Nicolas, et al.
Publicado: (2021)

Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia
por: Takase, Masayuki, et al.
Publicado: (2015)

High national rates of high-dose dopamine agonist prescribing for restless legs syndrome
por: Winkelman, John W
Publicado: (2021)

Active-State Model of a Dopamine D(2) Receptor - Gα(i) Complex Stabilized by Aripiprazole-Type Partial Agonists
por: Kling, Ralf C., et al.
Publicado: (2014)

The effects of dopamine and dopamine receptor agonists on the phototransduction cascade of frog rods
por: Nikolaeva, Darya A., et al.
Publicado: (2019)

Antipsychotics with similar association kinetics at dopamine D(2) receptors differ in extrapyramidal side-effects
por: Zeberg, Hugo, et al.
Publicado: (2018)

Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects
por: Breuer, Aviva, et al.
Publicado: (2016)

SUN-444 Efficacy and Safety of Dopamine Agonists in Psychiatric Patients Treated with Antipsychotics and Presenting a Macroprolactinoma
por: Allard, Lucie, et al.
Publicado: (2019)

17.4 POSSIBLE MECHANISMS INVOLVED IN THE ANTIPSYCHOTIC EFFECTS OF CANNABIDIOL (CBD)
por: Crippa, Jose Alexandre, et al.
Publicado: (2018)

Novel and Potent Dopamine D(2) Receptor Go-Protein Biased Agonists
por: Bonifazi, Alessandro, et al.
Publicado: (2019)

Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human
por: Wong, Yin Cheong, et al.
Publicado: (2019)

Reply to ‘Antipsychotics with similar association kinetics at dopamine D(2) receptors differ in extrapyramidal side-effects’
por: Sykes, David A., et al.
Publicado: (2018)

Dopamine D(2) receptors and the circadian clock reciprocally mediate antipsychotic drug-induced metabolic disturbances
por: Freyberg, Zachary, et al.
Publicado: (2017)

Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D(3) Receptors in the Brain in vivo
por: Kiss, Béla, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dn2j8isckjbj4u3s4l0ncoi08o